<DOC>
	<DOCNO>NCT01705938</DOCNO>
	<brief_summary>This randomize , phase 1 , single-blind , placebo-controlled , randomize , sequential , escalate , single-dose , study design evaluate safety , tolerability , pharmacodynamics ( PD ) pharmacokinetics ( PK ) property orally administer SP-333 tablet .</brief_summary>
	<brief_title>Single Ascending Dose Study Evaluate Safety , Tolerability Pharmacokinetics ( PK ) SP-333 Tablets Healthy Adult Subjects</brief_title>
	<detailed_description>This randomize , phase 1 , single-blind , placebo control , single-dose , study design evaluate safety , tolerability , pharmacokinetic property orally administer SP-333 tablet . The study include 7 group 8 subject ( 6 active , 2 placebo ) give single oral dose SP-333 tablet placebo . Following outpatient screen approximately 5 42 day dose , subject enter Clinical Pharmacology Unit ( CPU ) house least 48 hour , dose 48 hour dose . Subjects give single dose study drug day dose remain CPU least 48 hour . Subjects return CPU Days 8±1 15±1 safety follow . Safety Committee Meetings conduct review safety , tolerability , available Pharmacokinetic data current previous treatment group ( ) , prior dose subsequent treatment group . Subjects give treatment group consider completers complete Day 15±1 day Follow Visit .</detailed_description>
	<criteria>1 . Male female subject 18 55 year old 2 . Body weight great equal 50 kg ( 110 pound ) Body Mass Index ( BMI ) range 18 30 kg/ m2 3 . Medically healthy clinically significant finding . 4 . Subjects must bowel habit consider regular ( study minimum 4 bowel movement week without laxative ) . 5 . Subject must bowel movement , without laxative , 3 day administration study drug . 6 . Male subject female sexual partner childbearing potential must agree use highly effective contraceptive method study . 7 . Female subject must postmenopausal pregnant . 8 . Subjects must understand agree comply requirement study must willing sign Informed Consent Form . 1 . Smokers user nicotine product agree smoke use nicotine product stay CPU . 2 . Current history clinically significant disease , include gastrointestinal , renal , hepatic , neurologic ( e.g. , neuropathy ) , hematologic , endocrine ( e.g. , diabetes ) , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease condition . 3 . Presence abnormal clinically significant laboratory . 4 . History serious allergic reaction medication 5 . Certain abnormality ECG . 6 . Participated previous clinical study investigational product within 30 day study Participation 7 . Donated blood , blood component significant loss blood within 2 month dose 8 . History clinicallysignificant illness within 4 week dose 9 . Special diet , dietary habit , restriction , , may interfere conduct study health subject within 30 day dose 10 . History clinicallysignificant drug alcohol abuse within 2 year study participation 11 . Positive urine screen prohibit drug ( cocaine , cannabinoids , opiate , barbiturate , amphetamine , benzodiazepine , phencyclidine , propoxyphene ) . 12 . History human immunodeficiency virus ( HIV ) , hepatitis B surface antigen positive ( +HBsAg ) , hepatitis C antibody positive ( +HCVAb ) . 13 . History certain surgery : Gastric bypass surgery invasive procedure treatment obesity surgery remove segment gastrointestinal ( GI ) tract time . Patients gastric band ( unless band completely remove 60 day ) Surgery abdomen , pelvis retroperitoneal structure within six month study participation . Appendectomy , Instrumentation bowel , major surgery within 60 day study participation . 14 . Female subject childbearing potential breastfeeding 15 . Use routine systemic medication , include counter ( OTC ) medication within 2 week dose 16 . Use herbal product , dietary supplement , vitamin , grapefruit , grapefruit containing product within 2 week dose 17 . Irregular daily bowel habit 18 . Any issue , judgment investigator , make subject ineligible study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>